サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1756009

痛風治療の世界市場：薬剤クラス別、病状別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年

Global Gout Therapeutics Market Assessment, By Drug Class, By Disease Condition, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 238 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
痛風治療の世界市場：薬剤クラス別、病状別、投与経路別、流通チャネル別、地域別、機会、予測、2018年～2032年
出版日: 2025年06月25日
発行: Markets & Data
ページ情報: 英文 238 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の痛風治療の市場規模は、予測期間の2025年～2032年に6.91%のCAGRで拡大し、2024年の30億2,000万米ドルから2032年には51億5,000万米ドルに成長すると予測されています。世界の痛風治療市場成長は、痛風の有病率の上昇と治療オプションの進歩により上昇すると予測されます。

世界の痛風治療市場は、痛風患者の増加と体内尿酸値の上昇により急速に拡大しています。高齢化とともに肥満率の上昇や不健康な食事パターンが相まって痛風患者が増加しており、より優れた治療ソリューションへのニーズが高まっています。研究開発者は新しい治療法を開発し続けており、市場開拓は抗炎症薬や鎮痛薬とともに尿酸降下薬による複数の治療アプローチを提供しています。業界の主要企業は、痛風患者、特に持続性痛風や治療が困難な痛風患者の健康結果を向上させる革新的な解決策を生み出すために資金を投入しています。医療専門家は、新たな阻害剤とともに生物学的療法を、現在の標準的な治療アプローチに取って代わる画期的なソリューションとして認識しています。市場の成長を支えているのは、診断システムの充実と痛風に対する一般市民の意識の高まりであり、これにより迅速な治療介入が可能となります。先進国の高度な医療システムにより、最新の痛風治療オプションの導入が可能となり、より広範なヘルスケアの利用が可能となることで、新たな成長の可能性が生まれます。市場の競合環境は、製薬企業が戦略的パートナーシップを確立しながら規制当局の承認を得ることによって形成されます。さらに、痛風治療市場を支えるために、企業は他国でのプレゼンスを拡大しつつあります。例えば、2024年12月、Eisai Co., Ltd.は、高尿酸血症の痛風患者を治療するためのウレウスについて、中国の国家医薬品監督管理局（National Medical Products Administration）から承認を取得しました。

当レポートでは、世界の痛風治療市場について調査し、市場の概要とともに、薬剤クラス別、病状別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の痛風治療市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
    • 薬剤クラス別
      • 非ステロイド性抗炎症薬（NSAID）
      • コルチコステロイド
      • コルヒチン
      • 尿酸降下薬
      • 生物学的製剤
      • その他
    • 病状別
      • 急性痛風
      • 慢性痛風
    • 投与経路
      • 経口
      • 非経口
      • その他
    • 流通チャネル別
      • 病院薬局
      • 小売薬局
      • オンライン薬局
      • eコマース
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
  • 2024年の市場マップ分析

第6章 北米の痛風治療市場の見通し、2018年～2032年

  • 市場規模分析と予測
  • 市場シェア分析と予測
  • 国別市場評価
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の痛風治療市場の見通し、2018年～2032年

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の痛風治療市場の見通し、2018年～2032年

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の痛風治療市場の見通し、2018年～2032年

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの痛風治療市場の見通し、2018年～2032年

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場の促進要因
  • 市場の課題

第17章 市場動向と発展

第18章 規制の枠組み

  • 臨床試験
  • 規制当局の承認

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要企業トップ10の情勢
    • Merck & Co., Inc.
    • Sanofi S.A.
    • Regeneron Pharmaceuticals, Inc.
    • Novartis AG
    • AstraZeneca PLC
    • Astellas Pharma Inc.
    • Takeda Pharmaceutical Company Limited
    • Hikma Pharmaceuticals PLC
    • BioCryst Pharmaceuticals, Inc.
    • Selecta Biosciences Inc.

第22章 戦略的提言

第23章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 4. Global Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 5. Global Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 6. Global Gout Therapeutic Market Share (%), By Region, 2018-2032F
  • Figure 7. North America Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 8. North America Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 9. North America Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 10. North America Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 11. North America Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. North America Gout Therapeutic Market Share (%), By Country, 2018-2032F
  • Figure 13. United States Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 14. United States Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 15. United States Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 16. United States Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 17. United States Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Canada Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Canada Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 20. Canada Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 21. Canada Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Canada Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Mexico Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Mexico Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Mexico Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 26. Mexico Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 27. Mexico Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Europe Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Europe Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 30. Europe Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 31. Europe Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 32. Europe Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 33. Europe Gout Therapeutic Market Share (%), By Country, 2018-2032F
  • Figure 34. Germany Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Germany Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 36. Germany Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 37. Germany Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 38. Germany Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 39. France Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 40. France Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 41. France Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 42. France Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. France Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Italy Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Italy Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 46. Italy Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 47. Italy Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 48. Italy Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. United Kingdom Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. United Kingdom Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 51. United Kingdom Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 52. United Kingdom Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 53. United Kingdom Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 54. Russia Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 55. Russia Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 56. Russia Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 57. Russia Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 58. Russia Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Netherlands Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Netherlands Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 61. Netherlands Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 62. Netherlands Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Netherlands Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Spain Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Spain Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 66. Spain Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 67. Spain Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 68. Spain Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Turkey Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Turkey Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 71. Turkey Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 72. Turkey Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 73. Turkey Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 74. Poland Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 75. Poland Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 76. Poland Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 77. Poland Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 78. Poland Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 79. South America Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 80. South America Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 81. South America Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 82. South America Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 83. South America Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. South America Gout Therapeutic Market Share (%), By Country, 2018-2032F
  • Figure 85. Brazil Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Brazil Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 87. Brazil Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 88. Brazil Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 89. Brazil Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Argentina Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 91. Argentina Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 92. Argentina Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 93. Argentina Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 94. Argentina Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 95. Asia-Pacific Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 96. Asia-Pacific Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 97. Asia-Pacific Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 98. Asia-Pacific Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 99. Asia-Pacific Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. Asia-Pacific Gout Therapeutic Market Share (%), By Country, 2018-2032F
  • Figure 101. India Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. India Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 103. India Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 104. India Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 105. India Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 106. China Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. China Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 108. China Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 109. China Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 110. China Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 111. Japan Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 112. Japan Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 113. Japan Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 114. Japan Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 115. Japan Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 116. Australia Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 117. Australia Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 118. Australia Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 119. Australia Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 120. Australia Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 121. Vietnam Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 122. Vietnam Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 123. Vietnam Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 124. Vietnam Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 125. Vietnam Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 126. South Korea Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 127. South Korea Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 128. South Korea Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 129. South Korea Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Korea Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. Indonesia Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 132. Indonesia Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 133. Indonesia Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 134. Indonesia Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 135. Indonesia Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 136. Philippines Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 137. Philippines Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 138. Philippines Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 139. Philippines Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 140. Philippines Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 141. Middle East & Africa Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 142. Middle East & Africa Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 143. Middle East & Africa Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 144. Middle East & Africa Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 145. Middle East & Africa Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 146. Middle East & Africa Gout Therapeutic Market Share (%), By Country, 2018-2032F
  • Figure 147. Saudi Arabia Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 148. Saudi Arabia Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 149. Saudi Arabia Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 150. Saudi Arabia Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 151. Saudi Arabia Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 152. UAE Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 153. UAE Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 154. UAE Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 155. UAE Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 156. UAE Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 157. South Africa Gout Therapeutic Market, By Value, In USD Billion, 2018-2032F
  • Figure 158. South Africa Gout Therapeutic Market Share (%), By Drug Class, 2018-2032F
  • Figure 159. South Africa Gout Therapeutic Market Share (%), By Disease Condition, 2018-2032F
  • Figure 160. South Africa Gout Therapeutic Market Share (%), By Route of Administration, 2018-2032F
  • Figure 161. South Africa Gout Therapeutic Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 162. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 163. By Disease Condition Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024
目次
Product Code: MX13433

Global gout therapeutics market is projected to witness a CAGR of 6.91% during the forecast period 2025-2032, growing from USD 3.02 billion in 2024 to USD 5.15 billion in 2032. The global gout therapeutics market growth is projected to rise owing to the rising prevalence of gout and advancements in treatment options.

The global gout treatment market is experiencing fast expansion because of rising gout cases and rising body uric acid levels. The combination of rising obesity rates and unhealthy eating patterns alongside aging populations has resulted in more gout cases, thus driving the need for better treatment solutions. Research scientists continue to develop new therapeutic methods while the market provides multiple treatment approaches through urate-lowering medications, together with anti-inflammatory and pain control drugs. The leading companies in the industry dedicate funds to create innovative solutions that enhance health results for gout patients, particularly those who experience persistent or challenging-to-treat gout. Medical professionals identify biological therapies, along with new inhibitors, as revolutionary solutions that would replace current standard treatment approaches. The market growth receives support from enhanced diagnostic systems along with increasing public awareness of gout, which allows for prompt treatment interventions. The advanced medical systems in developed nations enable them to implement modern gout treatment options, which create new growth possibilities through wider healthcare availability. The market's competitive environment gets shaped by pharmaceutical companies obtaining regulatory approvals while establishing strategic partnerships. Additionally, to support the gout therapeutics market, companies are expanding their presence in other countries. For instance, in December 2024, Eisai Co., Ltd. received approval from the National Medical Products Administration in China for URECE to treat gout patients with hyperuricemia.

Rising Gout Cases Drive Therapeutic Market Growth

The increasing prevalence of gout worldwide drives substantial market expansion through multiple contributing factors. People eat purine-rich foods while drinking more alcohol and avoiding exercise, which together raises uric acid levels that cause gout. The worldwide rise in gout patients emerges because populations grow older, obesity rates increase, and hypertension and diabetes become more prevalent, since these conditions serve as known disease risk factors. The growing number of disease cases, along with improved diagnostic methods and increased disease knowledge, created substantial demand for traditional and novel treatment approaches. Pharmaceutical companies develop new therapeutic solutions and enhance medication distribution to emerging regions where gout rates continue to rise. The market experiences substantial growth because manufacturers and healthcare providers focus on developing solutions that treat both sudden gout flare-ups and ongoing disease control.

Furthermore, to increase the prevalence of gout therapy among people, companies participate in awareness programs. For instance, in May 2025, Atom Therapeutics Ltd. joined the Gout Education Society in Gout Awareness Day programs to educate people about the factors and treatment of this disease.

Advancements in Therapeutic Drugs Boost Market Demand

The gout therapeutics market is expanding quickly because of new drug development alongside advanced treatment solutions. Modern next-generation xanthine oxidase inhibitors, together with improved uricosuric agents and biologic therapies (recombinant uricase enzymes such as pegloticase), have revolutionized disease management for refractory cases. Modern gout treatments offer better effectiveness together with fewer side effects and make it easier for patients to stick with their treatment plans. The use of combination therapies along with personalized medicine approaches leads to better treatment outcomes. Standard medicinal therapies receive additional research and development resources from pharmaceutical companies for developing solutions that address patients who do not respond to these treatments. Advanced therapy across the globe is rising because healthcare organizations apply regulatory-approved treatment options. The ongoing development creates broader treatment accessibility while driving market expansion, which establishes gout therapeutics as a fast-growing pharmaceutical industry sector. Additionally, to support a pharmaceutical company in the advanced treatment of gout. For instance, in May 2025, XORTX Therapeutics Inc. announced plans to execute a non-brokered private placement that would produce USD 3 million by selling common share units. The money from this offer supports two main objectives: funding the gout therapeutic program development and meeting essential business requirements. XORTX pursues this strategic initiative to achieve better financial stability while advancing its pharmaceutical industry development work, which targets gout and kidney disease therapies.

Hospital Pharmacies Hold Largest Global Gout Therapeutics Market Shares

Hospital pharmacies hold the strongest position as the primary distribution channel, which generates the highest revenue in the gout therapeutics market. The market leader derives its position through multiple fundamental reasons, which include that hospitals are essential for managing severe gout conditions and biologic infusions such as pegloticase for difficult-to-treat chronic gout and sudden flare-ups. Medical facilities specifically manage high-cost treatments, together with injectable drugs, which need professional medical monitoring. Hospitalizations for gout-related complications, including tophaceous gout and kidney stones, have increased, thus increasing patient demand through this distribution channel. The pattern shows strong prevalence in developed countries that possess advanced healthcare systems due to hospitals' function as primary centers for both initial diagnosis and treatment commencement. Hospital pharmacies continue to lead the market because they provide specialized treatments with integrated physician supervision for acute cases, despite retail and online pharmacies expanding their presence in chronic maintenance medication. The gout treatment ecosystem requires these institutions to function as essential components for advanced therapies and acute interventions.

For instance, in May 2025, ANI Pharmaceuticals, Inc. announced a Phase 4 clinical trial at Massachusetts General Hospital, which evaluates the safety profile and treatment effectiveness of two dose levels (40 USP units and 80 USP units) of Purified Cortrophin Gel (repository corticotropin injection USP) (Cortrophin Gel) for acute gout flare management. The medical indication for Cortrophin Gel includes brief use as an auxiliary treatment during acute gouty arthritis attacks. Patients should avoid using Cortrophin Gel through intravenous routes.

North America Dominates the Gout Therapeutic Market

The North America gout therapeutic market leads because of various factors, which include high gout rates, together with modern healthcare systems and substantial R&D funding. The United States, together with Canada, forms the main gout patient base because obesity, combined with unhealthy eating and growing age populations, leads to increased gout cases. The strong pharmaceutical industry, together with a solid regulatory system, enables speedy approval and widespread use of new medical treatments. The healthcare system delivers modern treatments to numerous patients while widespread gout awareness programs fuel market growth. Through insurance and reimbursement systems, patients receive affordable treatment options that become accessible to them. North America maintains its position as the leading gout therapeutic market because fresh biological and urate-lowering therapies entered the market while clinical trials continue. Multiple market-driving factors combine to make this region the most significant and dynamic gout treatment market. Additionally, to support this region, market players have successfully launched their clinical trials to increase market growth. For instance, in June 2025, Zydus Lifesciences Limited announced its phase II clinical trial of NLRP3 inhibitor Usnoflast (ZYIL1) in patients with Amyotrophic Lateral Sclerosis.

Impact of U.S. Tariffs on the Global Gout Therapeutics Market

The U.S. tariff effects on the global gout therapeutics market are due to instability through elevated prices and disrupted supply chain operations. Generic gout medications, including allopurinol and febuxostat, utilize active pharmaceutical ingredients (APIs) provided from China and India. These manufacturers of gout therapeutics will be subject to major price increases if tariffs are introduced on APIs. In turn, this will likely lead to countrywide shortages (no medicine at any price), increased treatment costs, and limited access for uninsured populations, including ancillary medications that treat other annual curative care costs, mostly statins and diuretics. Eventually, supply chains will have to change manufacturers, but that is a long way off, especially considering a market that is likely already saturated and the costs of changing their supply chain limit affordability and pressure healthcare systems and access. The long-term impact depends on tariff exemptions and how quickly supply chains adapt to new trade policies.

Key Players Landscape and Outlook

The global market for gout treatment maintains a constant state of innovation due to companies striving to finish ahead of their competitors in drug development, especially for refractory and chronic gout with advanced biologics and enhanced urate-lowering therapies. The fast-paced market will see rising competition from new technologies and partnerships between industry players. In March 2023, Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Sobi) declared the Phase 3 DISSOLVE I & II trial results that demonstrated positive outcomes for SEL-212 doses in adult patients with chronic refractory gout.

In August 2024, Arthrosi Therapeutics Inc., a late-stage biotechnology firm that created an advanced URAT1 inhibitor for gout treatment, received FDA Fast Track Designation for AR882 to treat clinically detectable tophi in gout patients.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Gout Therapeutics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 5.2.1.2. Corticosteroids
      • 5.2.1.3. Colchicine
      • 5.2.1.4. Urate-Lowering Agents
      • 5.2.1.5. Biologics
      • 5.2.1.6. Other Drug Classes
    • 5.2.2. By Disease Condition
      • 5.2.2.1. Acute Gout
      • 5.2.2.2. Chronic Gout
    • 5.2.3. By Route of Administration
      • 5.2.3.1. Oral
      • 5.2.3.2. Parenteral
      • 5.2.3.3. Other Routes
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospital Pharmacies
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Online Pharmacies
      • 5.2.4.4. E-commerce
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East and Africa
    • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Drug Class
    • 5.3.2. By Disease Condition
    • 5.3.3. By Route of Administration
    • 5.3.4. By Distribution Channel
    • 5.3.5. By Region

6. North America Gout Therapeutics Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Drug Class
      • 6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • 6.2.1.2. Corticosteroids
      • 6.2.1.3. Colchicine
      • 6.2.1.4. Urate-Lowering Agents
      • 6.2.1.5. Biologics
      • 6.2.1.6. Other Drug Classes
    • 6.2.2. By Disease Condition
      • 6.2.2.1. Acute Gout
      • 6.2.2.2. Chronic Gout
    • 6.2.3. By Route of Administration
      • 6.2.3.1. Oral
      • 6.2.3.2. Parenteral
      • 6.2.3.3. Other Routes
    • 6.2.4. By Distribution Channel
      • 6.2.4.1. Hospital Pharmacies
      • 6.2.4.2. Retail Pharmacies
      • 6.2.4.3. Online Pharmacies
      • 6.2.4.4. E-commerce
    • 6.2.5. By Country Share
      • 6.2.5.1. United States
      • 6.2.5.2. Canada
      • 6.2.5.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Gout Therapeutics Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Drug Class
          • 6.3.1.2.1.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
          • 6.3.1.2.1.2. Corticosteroids
          • 6.3.1.2.1.3. Colchicine
          • 6.3.1.2.1.4. Urate-Lowering Agents
          • 6.3.1.2.1.5. Biologics
          • 6.3.1.2.1.6. Other Drug Classes
        • 6.3.1.2.2. By Disease Condition
          • 6.3.1.2.2.1. Acute Gout
          • 6.3.1.2.2.2. Chronic Gout
        • 6.3.1.2.3. By Route of Administration
          • 6.3.1.2.3.1. Oral
          • 6.3.1.2.3.2. Parenteral
          • 6.3.1.2.3.3. Other Routes
        • 6.3.1.2.4. By Distribution Channel
          • 6.3.1.2.4.1. Hospital Pharmacies
          • 6.3.1.2.4.2. Retail Pharmacies
          • 6.3.1.2.4.3. Online Pharmacies
          • 6.3.1.2.4.4. E-commerce
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Gout Therapeutics Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Gout Therapeutics Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Gout Therapeutics Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Gout Therapeutics Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

  • 18.1. Clinical Trials
  • 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

  • 21.1. Competition Matrix of Top 5 Market Leaders
  • 21.2. SWOT Analysis for Top 5 Players
  • 21.3. Key Players Landscape for Top 10 Market Players
    • 21.3.1. Merck & Co., Inc.
      • 21.3.1.1. Company Details
      • 21.3.1.2. Key Management Personnel
      • 21.3.1.3. Products and Services
      • 21.3.1.4. Financials (As Reported)
      • 21.3.1.5. Key Market Focus and Geographical Presence
      • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 21.3.2. Sanofi S.A.
    • 21.3.3. Regeneron Pharmaceuticals, Inc.
    • 21.3.4. Novartis AG
    • 21.3.5. AstraZeneca PLC
    • 21.3.6. Astellas Pharma Inc.
    • 21.3.7. Takeda Pharmaceutical Company Limited
    • 21.3.8. Hikma Pharmaceuticals PLC
    • 21.3.9. BioCryst Pharmaceuticals, Inc.
    • 21.3.10. Selecta Biosciences Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer